No products in the cart.
Pre-made Votumumab benchmark antibody (Radiolabelled antibody, anti-human carcinoma associated antigen CTAA16 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-1051
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-human carcinoma associated antigen CTAA16 therapeutic antibody (Pre-made Votumumab biosimilar, Radiolabelled antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.[1] It was developed for the detection of colorectal tumors, but has never been marketed.[2]
| Products Name (INN Index) | Pre-Made Votumumab Biosimilar, Radiolabelled Antibody: Anti-Human Carcinoma Associated Antigen Ctaa16 therapeutic antibody |
|---|---|
| INN Name | votumumab |
| Target | human carcinoma associated antigen CTAA16 |
| Format | Radiolabelled antibody |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG3 – kappa |
| VD LC | IgG3 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Organon Teknika Corp. (Durham NC USA) / KS Biomedix Ltd (Guildford UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | human carcinoma associated antigen CTAA16 |
| Package |
Previous slide
Next slide
